Development of a Liquid Chromatography High Resolution Mass Spectrometry (LC-HRMS) Method for the Quantitation of Viral Envelope Glycoprotein in Ebola Virus-Like Particle Vaccine Preparations
OSTP Journal Article
USAMRIID Frederick United States
Pagination or Media Count:
Ebola virus like particles EBOV VLPs, eVLPs, are produced by expressing the viral transmembrane glycoprotein GP and the structural matrix protein VP40 in mammalian cells. When expressed, these proteins self-assemble and bud from host cells displaying morphology similar to infectious virions. Several studies have shown that rodents and non-human primates vaccinated with eVLPs are protected from lethal EBOV challenge. The mucin-like domain of envelope glycoprotein GP1 serves as the major target for a productive humoral immune response. Therefore GP1 concentration is a critical quality attribute of EBOV vaccines and accurate measurement of the amount of GP1 present in eVLP lots is crucial to understanding variability in vaccine efficacy.
- Medicine and Medical Research